Full disruption: How digitalisation is transforming medtech
Add BT as a preferred source
Anupama Puranik
DIGITALISATION has come (relatively) late to the medical devices industry, but it is now here. Building since the beginning of the last decade, breaking through with the Covid crisis, the ‘resultant vector’ of disruption will accelerate as we move deeper into the 2020s. The ultimate imperative is to have a leadership team in place that can leverage innovative technologies within the context of a broader strategic vision. Those stewarding medtech companies will thus have to (often radically) rethink their approach not just to technology, but to their business models, talent, and transformation of mission and culture.
Digitalisation will inexorably separate medtech companies into two camps: those able to transform themselves internally to differentiate their offerings in a dramatically expanded market and firms that are falling behind, that will either be acquired or forced into transactional portions of the value chain.
TRENDING NOW
Trickier across borders: Why commercial disputes are getting more complex
Too little, too late? Manila’s billion-dollar bid to ignite its sputtering EV industry
When every phone becomes a satellite phone, what happens to Asia’s telcos?
How BYD disrupted Singapore’s car market – and why the strategy is turning on itself
